24 related articles for article (PubMed ID: 26839207)
1. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.
Rimondi E; Valencic E; Tommasini A; Secchiero P; Melloni E; Marcuzzi A
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680069
[TBL] [Abstract][Full Text] [Related]
2. Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.
Ha NT; Lee CH
Cells; 2020 Oct; 9(11):. PubMed ID: 33113804
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.
Ebihara T; Takeuchi T; Moriya Y; Tagawa Y; Kondo T; Moriwaki T; Asahi S
Drug Res (Stuttg); 2016 Jun; 66(6):316-23. PubMed ID: 27011383
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of alpha-phosphonosulfonate squalene synthase inhibitors. I. Disposition of a farnesylethyl alpha-phosphonosulfonate and ester prodrugs in rats.
Lan SJ; Hsieh DC; Hillyer JW; Fancher RM; Rinehart KJ; Warrack BM; White RE
Drug Metab Dispos; 1998 Oct; 26(10):993-1000. PubMed ID: 9763405
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
Kogame A; Takeuchi T; Nonaka M; Yamasaki H; Kawaguchi N; Bernards A; Tagawa Y; Morohashi A; Kondo T; Moriwaki T; Asahi S
Xenobiotica; 2017 Mar; 47(3):255-266. PubMed ID: 27225050
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.
Ebihara T; Teshima K; Kondo T; Tagawa Y; Moriwaki T; Asahi S
Drug Res (Stuttg); 2016 Jun; 66(6):287-92. PubMed ID: 26839207
[TBL] [Abstract][Full Text] [Related]
8. Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia.
Burnett JR
Curr Opin Investig Drugs; 2006 Sep; 7(9):850-6. PubMed ID: 17002264
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S; Frishman WH
Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
[TBL] [Abstract][Full Text] [Related]
10. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice.
Marcuzzi A; Loganes C; Celeghini C; Kleiner G
Curr Med Chem; 2018; 25(24):2783-2796. PubMed ID: 28901277
[TBL] [Abstract][Full Text] [Related]
11. Emerging lipid-lowering drugs: squalene synthase inhibitors.
Elsayed RK; Evans JD
Expert Opin Emerg Drugs; 2008 Jun; 13(2):309-22. PubMed ID: 18537523
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
